Build vs Buy: When to Hire a Clinical Supply Consultant vs Build the Function In-House

Every growing biotech reaches the same fork in the road. The clinical supply chain has become too complex and too consequential to keep handling off the side of someone's desk — and now there's a decision to make. Do you hire and build an internal supply function, or bring in a consultant or partner who already has the expertise?

It's worth being honest up front: this is a post written by a consultancy, so you'd be right to expect it to say "hire a consultant." Instead, here's the genuinely useful version — a clear-eyed look at when building in-house is the right call, when bringing in outside expertise is, and how to tell which situation you're actually in. The wrong answer here is expensive either way, so the decision deserves more than a default.

Why this is a real decision, not a formality

Clinical supply chain management is a specialized discipline. It requires deep, current knowledge of forecasting, packaging strategy, cold chain, vendor oversight, regulatory compliance, and the operational judgment that only comes from having seen trials go wrong. That expertise is scarce, expensive to hire, and takes years to develop internally.

At the same time, the need for it is often uneven. A company running its first pivotal trial has an intense, immediate requirement that may look very different a year later. Matching a permanent hire to a variable need is exactly the kind of decision that rewards thinking it through — and punishes defaulting.

When building in-house makes sense

Building an internal clinical supply function is the right move when the conditions genuinely support it:

• You have sustained, ongoing volume. If you're running multiple trials continuously and expect to for years, the workload can justify permanent headcount.
• Supply chain is core to your long-term strategy. Companies planning to commercialize and build lasting operational capability benefit from institutional knowledge that stays in-house.
• You can actually attract and retain the expertise. Experienced clinical supply professionals are in demand. Building in-house only works if you can genuinely hire good people and keep them challenged — a single hire who then becomes a single point of failure is a real risk.
• You have time to build. Developing an internal function is a multi-year investment. If your need is years out, you can build deliberately.

The honest caveat: many emerging biotechs assume they should build because it feels more "grown up," then discover they've hired one overstretched person to cover a discipline that really needs a team's worth of experience.

When bringing in a consultant or partner makes sense

Outside expertise tends to be the better fit when:

• The need is immediate and the timeline is tight. You can't hire, onboard, and season an internal team fast enough for a trial starting now. Experienced help lets you tap decades of know-how immediately.
• The need is variable or project-based. If your requirement spikes for a pivotal trial and eases afterward, flexible expertise fits the shape of the work far better than fixed headcount.
• You need a breadth one person can't cover. Clinical supply spans forecasting, cold chain, regulatory, vendor oversight, and more. A partner brings range that's hard to replicate in an early internal hire.
• You want to de-risk a critical, first-of-its-kind program. Running your first cell therapy trial, or your first multi-country study, is exactly when experience prevents expensive mistakes — and when learning on the job is riskiest.
• You're building in-house but not there yet. Outside help can carry the function now and help you build the internal capability for later — rather than leaving you exposed in the gap.

The option most people miss: the hybrid model

The framing of "build or buy" is a bit of a false binary. In practice, the strongest approach is frequently a hybrid: a lean internal team that owns strategy and continuity, supported by outside expertise for specialized needs, peak loads, or critical programs.

This gives you institutional knowledge where it matters and flexible depth where you need it — without over-hiring for peaks you can't sustain or under-resourcing a critical trial. For many growing companies, the real question isn't "build or buy" but "what's the right mix, and how does it change as we scale?"

How to decide: the questions that actually matter

Work through these honestly:

1. How permanent is the need? Ongoing for years, or intense-then-variable? Permanent needs lean build; variable needs lean buy.
2. How fast do you need capability? Now leans buy; years out allows build.
3. Can you genuinely hire and retain the expertise? If not, building is a plan, not a capability.
4. How critical and novel is the immediate work? High-stakes, first-of-its-kind programs favor proven experience.
5. What's the real cost of each? Compare not just salary vs. fees, but the cost of a mistake, of slow ramp-up, of a single point of failure, or of over-hiring.
6. What's your endgame? If you're heading toward commercialization, factor in the capability you'll need then, not just now.